Response monitoring with DCE-MRI, H215O-PET and 18FDG-PET in patients with advanced NSCLC treated with bevacizumab and erlotinib

摘要: 3638 Background:
 Efficacy of targeted drugs by RECIST criteria may underestimate their clinical value. The aim of the current study was to evaluate whether early response to treatment with bevacizumab and erlotinib in patients with advanced NSCLC can be assessed with 18FDG-PET, H215O-PET and DCE-MRI.
 Methods:
 In a multicenter phase II study, chemonaive patients with advanced non-squamous NSCLC were treated with bevacizumab 15 mg/kg q 3 week and erlotinib 150 mg daily until progression. Primary endpoint was non-progression rate (NPR) at 6 weeks posttreatment.
 Patients underwent dynamic 18FDG-PET, H215O-PET and CE-MRI scanning as well as CT at baseline and after 3 and 6 weeks of treatment.
 RECIST measurements at CT, standard uptake value (SUV) at 18FDG-PET, tumor perfusion (F) at H215O-PET and the endothelial transfer constant (Kps) at DCE-MRI were …